| Identification | Back Directory | [Name]
1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one | [CAS]
188116-07-6 | [Synonyms]
CS-1057
ELB-138
Imepitoin
AWD 131-13
AWD 131-138, >=98%
IMEPITOIN; AWD131-138
AWD 131-138(Imepitoin)
3-(4-chlorophenyl)-5-morpholin-4-yl-4H-imidazol-2-one
1-(4-CHLOROPHENYL)-4-MORPHOLINO-1H-IMIDAZOL-2(5H)-ONE
1-(4-chlorophenyl)-4-morpholin-4-yl-5H-imidazol-2-one
1-(4-chlorophenyl)-4-morpholino-1,5-dihydro-2H-imidazol-2-one
1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one
2H-Imidazol-2-one,1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-
Imepitoin
1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C13H14ClN3O2 | [MDL Number]
MFCD18450225 | [MOL File]
188116-07-6.mol | [Molecular Weight]
279.72 |
| Chemical Properties | Back Directory | [Melting point ]
264℃ (ethanol ) | [Boiling point ]
421.8±55.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMF:10.0(Max Conc. mg/mL);35.75(Max Conc. mM)
DMSO:17.5(Max Conc. mg/mL);62.56(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.79(Max Conc. mM)
Ethanol:1.13(Max Conc. mg/mL);4.02(Max Conc. mM) | [form ]
A crystalline solid | [pka]
4.39±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
1-(4-Chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one is used in treating feline epilepsy. | [Biological Activity]
Imepitoin (AWD 131-138; ELB 138) is a g-aminobutyric acid A (GABAA) receptor partial positive allosteric modulator (PAM) th at targets the benzodiazepine (BZD)-binding site at the α/γ2-interface. Imepitoin enhances GABA current (% response/[GABA] alone in μM/receptor complex = 320/3/α1β2γ2310/25/α1β3γ2460/8/α2β2γ2590/12/α3β2γ2 and 290/3/α5β2γ2 using Xenopus oocytes expressing respective r at receptor complex) with ~2% the potency and 17-27% the efficacy of diazepam toward α1β2γ2. Imepitoin exhibits in vivo therapeutic efficacy in animal models of seizure and epilepsy. | [in vivo]
AWD 131-138 did not produce midazolam-like responding or alter response rates at cumulative doses up to 18.0 mg/kg i.m. (plasma levels over 2100 ng/ml). When AWD 131-138 (10-100 microg/kg/injection) was studied by substitution, responding declined to vehicle substitution levels within three sessions. At the dose of 100 microg/kg i.v. AWD 131-138, sufficient drug was self-administered during the first session (about 3.5 mg/kg) to produce plasma levels above 1000 ng/ml, yet responding over the next two sessions dropped to vehicle levels [2]. Prolonged oral administration with twice-daily dosing of ELB 138 with either 5 or 40 mg/kg over a 5-week period was not associated with loss of anticonvulsant efficacy in the PTZ dog model [3]. |
|
|